Review the side-effects of Mirabegron as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

G_older_woman_urinary_incontinence Phase 4 trial showed that mirabegron significantly decreased incontinence episodes and micturitions compared with placebo among patients aged 65 years and older.

CHICAGO, May 5, 2019 /PRNewswire/ -- Astellas Pharma Inc. today announced results from the Phase 4, 12-week PLUS trial, the first large-scale, randomized trial in North America and Europe evaluating ...

The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization. The Food and Drug Administration ...

Mirabegron has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal ...

Antimuscarinics have remained the standard of care for patients with overactive bladder (OAB) syndrome for several decades, despite the fact that, owing to their adverse effects, these drugs are ...

Astellas Pharma US, Inc announced the results of a pivotal phase 3 clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB).

Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — Mirabegron, a beta-3 adrenoceptor agonist approved for treatment of overactive bladder, did not ...

The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization. The Food and Drug Administration ...

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the ...